title: The efficacy of radiotherapy in the treatment of intraocular metastases.
abstract: From January 1980 to May 1991, 28 patients with intraocular metastases were seen at our Institute. Three presented with bilateral metastases and two developed contralateral involvement. Out of the 33 ocular metastases 27 were managed by radiotherapy. The most common primary tumour sites were breast (18/28 patients) and lung (3/28). 22 patients were treated with an 8 MV linear accelerator, using a 4 x 4 cm anterior direct field. The median dose was 40 Gy/20 fractions (range 28 Gy/14 fractions to 50 Gy/25 fractions). Of the 27 treatments reported, 16 resulted in a complete response (59%), six in a partial response (22%) and five resulted in no change (19%). Complete and partial responses lasted for a median time of 13 months (range of 3-89+ months). The median survival time from the start of ocular treatment was 13 months. The aim of radiation treatment is either to prevent or to postpone the visual loss caused by intraocular metastases.
authors.affiliation: Radiotherapy Division, Centro di Riferimento Oncologico, Aviano (PN), Italy.
authors.forename: E
authors.initials: E
authors.lastname: Minatel
authors.forename: M G
authors.initials: MG
authors.lastname: Trovò
authors.forename: L
authors.initials: L
authors.lastname: Forner
authors.forename: G
authors.initials: G
authors.lastname: Franchin
authors.forename: A
authors.initials: A
authors.lastname: de Paoli
authors.forename: M
authors.initials: M
authors.lastname: Roncadin
authors.forename: C
authors.initials: C
authors.lastname: Gobitti
authors.forename: G
authors.initials: G
authors.lastname: Bassignano
mesh_terms: D001943:Breast Neoplasms / Q000473:pathology; D002830:Choroid Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D005260:Female; D006801:Humans; D015811:Iris Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods*; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D015996:Survival Rate; D014792:Visual Acuity / Q000528:radiation effects